Volatile anaesthetics and cardioprotection - lessons from animal studies

Fundamental and Clinical Pharmacology

Volumn 27, Issue 1, 2013, Pages 21-34

  Muntean, Danina M ^a   Ordodi, Valentin ^a   Ferrera, René ^b   Angoulvant, Denis ^c  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Cardioprotection; Ischaemia reperfusion; Postconditioning; Preconditioning; Volatile anaesthetics

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ANESTHETIC AGENT; BRADYKININ; DIAZOXIDE; KETAMINE; SEVOFLURANE;

COMORBIDITY; DRUG EFFICACY; HEART MUSCLE INJURY; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ANESTHETICS, INHALATION; ANIMALS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; PROTECTIVE AGENTS; TRANSLATIONAL MEDICAL RESEARCH; VOLATILIZATION;

EID: 84872387229     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01055.x     Document Type: Review

References (91)

1. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. (2008) 88 581-609.
2. Hausenloy D.J., Yellon D.M. Clinical translation of cardioprotective strategies: report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection. Basic Res. Cardiol. (2008) 103 493-500.
3. Piot C., Croisille P., Staat P. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. (2008) 359 473-481.
4. Ruiz-Meana M., Garcia-Dorado D. Translational cardiovascular medicine (II). Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Rev. Esp. Cardiol. (2009) 62 199-209.
5. Staat P., Rioufol G., Piot C. et al. Postconditioning the human heart. Circulation (2005) 112 2143-2148.
6. Tissier R., Berdeaux A., Ghaleh B. et al. Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci. (2008) 13 284-301.
7. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 74 1124-1136.
8. Wojtovich A.P., Burwell L.S., Sherman T.A., Nehrke K.W., Brookes P.S. The C. elegans mitochondrial K+(ATP) channel: a potential target for preconditioning. Biochem. Biophys. Res. Commun. (2008) 376 625-628.
9. Zhao Z.Q., Corvera J.S., Halkos M.E. et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart. Circ. Physiol. (2003) 285 H579-H588.
10. Vinten-Johansen J., Granfeldt A., Mykytenko J., Undyala V.V., Dong Y., Przyklenk K. The multidimensional physiological responses to postconditioning. Antioxid. Redox Signal. (2011) 14 791-810.
11. Di Lisa F., Canton M., Carpi A. et al. Mitochondrial injury and protection in ischemic pre- and postconditioning. Antioxid. Redox Signal. (2011) 14 881-891.
12. De Hert S.G., Preckel B., Hollmann M.W., Schlack W.S. Drugs mediating myocardial protection. Eur. J. Anaesthesiol. (2009) 26 985-995.
13. Zaugg M., Lucchinetti E., Uecker M., Pasch T., Schaub M.C. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br. J. Anaesth. (2003) 91 551-565.
14. Riess M.L., Stowe D.F., Warltier D.C. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am. J. Physiol. Heart. Circ. Physiol. (2004) 286 H1603-H1607.
15. Bland J.H., Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology (1976) 45 287-293.
16. Spieckermann P.G., Braun U., Hellberg K. et al. [Survival and resuscitation time of the heart during ketamine, barbiturates and halothane anesthesia]. Z. Prakt. Anasth. (1970) 5 365-372.
17. Tanaka K., Ludwig L.M., Kersten J.R., Pagel P.S., Warltier D.C. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology (2004) 100 707-721.
18. Weber N., Schlack W. Inhalational anaesthetics and cardioprotection. in: Schutttler J., Schwilden H. (Eds), Handbook of experimental pharmacology. Springer-Verlag, Berlin, Heidelberg, 2008, pp. 187-207.
19. Suleiman M.S., Zacharowski K., Angelini G.D. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br. J. Pharmacol. (2008) 153 21-33.
20. De Hert S.G. Volatile anesthetics and cardiac function. Semin. Cardiothorac. Vasc. Anesth. (2006) 10 33-42.
21. Frassdorf J., De Hert S., Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br. J. Anaesth. (2009) 103 89-98.
22. Kersten J.R., Schmeling T.J., Pagel P.S., Gross G.J., Warltier D.C. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anaesthesiology (1997) 87 361-370.
23. Cason B.A., Gamperl A.K., Slocum R.E., Hickey R.F. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology (1997) 87 1182-1190.
24. Pratt P.F. Jr, Wang C., Weihrauch D. et al. Cardioprotection by volatile anesthetics: new applications for old drugs? Curr. Opin. Anaesthesiol. (2006) 19 397-403.
25. Schlack W., Hollmann M., Stunneck J., Thamer V. Effect of halothane on myocardial reoxygenation injury in the isolated rat heart. Br. J. Anaesth. (1996) 76 860-867.
26. Preckel B., Schlack W., Comfere T., Obal D., Barthel H., Thamer V. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br. J. Anaesth. (1998) 81 905-912.
27. Preckel B., Mullenheim J., Moloschavij A., Thamer V., Schlack W. Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth. Analg. (2000) 91 1327-1332.
28. Cohen M.V., Downey J.M. Ischemic postconditioning: from receptor to end-effector. Antioxid. Redox Signal. (2011) 14 821-831.
29. Stadnicka A., Marinovic J., Ljubkovic M., Bienengraeber M.W., Bosnjak Z.J. Volatile anesthetic-induced cardiac preconditioning. J Anesth. (2007) 21 212-219.
30. Sergeev P., da Silva R., Lucchinetti E. et al. Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology (2004) 100 474-488.
31. Garcia-Dorado D., Ruiz-Meana M., Piper H.M. Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues. Cardiovasc. Res. (2009) 83 165-168.
32. Cohen M.V. Efficacy of preconditioning should be gauged by reduction of infarction. Br. J. Pharmacol. (2004) 141 197-198.
33. Lochner A., Genade S., Moolman J.A. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res. Cardiol. (2003) 98 337-346.
34. Miura T., Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res. Cardiol. (2008) 103 501-513.
35. Riess M.L., Kevin L.G., Camara A.K., Heisner J.S., Stowe D.F. Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts. Anesthesiology (2004) 100 569-574.
36. Sandhu R., Diaz R.J., Mao G.D., Wilson G.J. Ischemic preconditioning: differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia. Circulation (1997) 96 984-995.
37. Lange M., Redel A., Lotz C. et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: role of beta 1- and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology (2009) 110 516-528.
38. Penna C., Mancardi D., Rastaldo R., Losano G., Pagliaro P. Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc. Res. (2007) 75 168-177.
39. Kin H., Zhao Z.Q., Sun H.Y. et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc. Res. (2004) 62 74-85.
40. Chiari P.C., Bienengraeber M.W., Pagel P.S., Krolikowski J.G., Kersten J.R., Warltier D.C. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology (2005) 102 102-109.
41. Ludwig L.M., Patel H.H., Gross G.J., Kersten J.R., Pagel P.S., Warltier D.C. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology (2003) 98 705-711.
42. Piriou V., Chiari P., Gateau-Roesch O. et al. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology (2004) 100 581-588.
43. Krolikowski J.G., Bienengraeber M., Weihrauch D., Warltier D.C., Kersten J.R., Pagel P.S. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesth. Analg. (2005) 101 1590-1596.
44. Pagel P.S. Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J. Cardiothorac. Vasc. Anesth. (2008) 22 753-765.
45. Hentia C., Gheorghiu G., Ordodi V. et al. Cardioprotection with Volatile Anaesthetics in Rat Hearts In Vivo: No Additive Effect of Cyclosporine A Administration at Reperfusion. in: Medimond International Proceedings B, Italy, (Ed.), Proceedings of the 8th International Congress on Coronary Artery Diseases "New Approaches in Coronary Artery Diseases", Prague, Czech Republic, 2009, pp. 547-551.
46. Piriou V., Chiari P., Lhuillier F. et al. Pharmacological preconditioning: comparison of desflurane, sevoflurane, isoflurane and halothane in rabbit myocardium. Br. J. Anaesth. (2002) 89 486-491.
47. Lange M., Smul T.M., Blomeyer C.A. et al. Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology (2006) 105 503-510.
48. Miura T., Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc. Drugs Ther. (2010) 24 255-263.
49. Pagel P.S., Krolikowski J.G., Neff D.A. et al. Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth. Analg. (2006) 102 1348-1354.
50. Zaugg M., Lucchinetti E., Spahn D.R., Pasch T., Schaub M.C. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology (2002) 97 4-14.
51. Kaneda K., Miyamae M., Sugioka S. et al. Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. Anesth. Analg. (2008) 106 9-16, table of contents.
52. Hanley P.J., Daut J. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J. Mol. Cell. Cardiol. (2005) 39 17-50.
53. Barthel H., Ebel D., Mullenheim J., Obal D., Preckel B., Schlack W. Effect of lidocaine on ischaemic preconditioning in isolated rat heart. Br. J. Anaesth. (2004) 93 698-704.
54. Yan M., Chen C., Zhang F., Chen G. Lidocaine abolishes the myocardial protective effect of sevoflurane post-conditioning. Acta Anaesthesiol. Scand. (2008) 52 111-116.
55. Molojavyi A., Preckel B., Comfere T., Mullenheim J., Thamer V., Schlack W. Effects of ketamine and its isomers on ischemic preconditioning in the isolated rat heart. Anesthesiology.(2001) 94, 623-629; discussion 5A-6A.
56. Mullenheim J., Rulands R., Wietschorke T., Frassdorf J., Preckel B., Schlack W. Late preconditioning is blocked by racemic ketamine, but not by S(+)-ketamine. Anesth. Analg. (2001) 93, 265-270.
57. Ordodi G., Gheorghiu G., Hentia C. et al. In vivo studies of cardioprotection induced by volatile anaesthetics - experimental model in rodents. Bulletin USAMV-CN. (2008) 65 401-405.
58. Gheorghiu G., Ordodi V., Hentia C. et al. Cardioprotection induced by anaesthetic postconditioning is blunted by high-dose ketamine. Cent. Eur. J. Occup. Environ. Med. (2009) 15 267-274.
59. Muntean D., Gheorghiu G., Ordodi V. et al. Ketamine dose-dependently interferes with diazoxide and anaesthetic pre- and postconditioning elicited cardioprotection. Eur. Heart J. (Abstract Supplement). (2009) 30 214.
60. Smul T.M., Stumpner J., Blomeyer C. et al. Propofol inhibits desflurane-induced preconditioning in rabbits. J. Cardiothorac. Vasc. Anesth. (2011) 25 276-281.
61. Patel H.H., Hsu A., Gross G.J. Attenuation of heat shock-induced cardioprotection by treatment with the opiate receptor antagonist naloxone. Am. J. Physiol. Heart. Circ. Physiol. (2002) 282 H2011-H2017.
62. Fradorf J., Huhn R., Weber N.C. et al. Sevoflurane-induced preconditioning: impact of protocol and aprotinin administration on infarct size and endothelial nitric-oxide synthase phosphorylation in the rat heart in vivo. Anesthesiology (2010) 113 1289-1298.
63. Abete P., Ferrara N., Cioppa A. et al. Preconditioning does not prevent postischemic dysfunction in aging heart. J. Am. Coll. Cardiol. (1996) 27 1777-1786.
64. Sniecinski R., Liu H. Reduced efficacy of volatile anesthetic preconditioning with advanced age in isolated rat myocardium. Anesthesiology (2004) 100 589-597.
65. Mio Y., Bienengraeber M.W., Marinovic J. et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology (2008) 108 612-620.
66. Tanaka K., Kawano T., Tomino T. et al. Mechanisms of impaired glucose tolerance and insulin secretion during isoflurane anesthesia. Anesthesiology (2009) 111 1044-1051.
67. Kehl F., Krolikowski J.G., Mraovic B., Pagel P.S., Warltier D.C., Kersten J.R. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology (2002) 96 183-188.
68. Tanaka K., Kehl F., Gu W., Krolikowski J.G., Pagel P.S., Warltier D.C. et al. Isoflurane-induced preconditioning is attenuated by diabetes. Am. J. Physiol. Heart. Circ. Physiol. (2002) 282 H2018-H2023.
69. Kehl F., Krolikowski J.G., Weihrauch D. et al. N-acetylcysteine restores isoflurane-induced preconditioning against myocardial infarction during hyperglycemia. Anesthesiology (2003) 98 1384-1390.
70. Huhn R., Heinen A., Weber N.C., Hollmann M.W., Schlack W., Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br. J. Anaesth. (2008) 100 465-471.
71. Huhn R., Heinen A., Hollmann M.W., Schlack W., Preckel B., Weber N.C. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr. Metab. Cardiovasc. Dis. (2010) 20 706-712.
72. Raphael J., Gozal Y., Navot N., Zuo Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J. Cardiovasc. Pharmacol. (2010) 55 348-357.
73. Feng J., Fischer G., Lucchinetti E. et al. Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: role of protein kinase B/Akt signaling. Anesthesiology (2006) 104 1004-1014.
74. Lucchinetti E., Jamnicki M., Fischer G., Zaugg M. Preconditioning by isoflurane retains its protection against ischemia-reperfusion injury in postinfarct remodeled rat hearts. Anesth. Analg. (2008) 106 17-23, table of contents.
75. Gibbons R.J., Valeti U.S., Araoz P.A., Jaffe A.S. The quantification of infarct size. J. Am. Coll. Cardiol. (2004) 44 1533-1542.
76. Bolli R., Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. (1999) 79 609-634.
77. Costa M.A., Carere R.G., Lichtenstein S.V. et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation (2001) 104 2689-2693.
78. Fellahi J.L., Gue X., Richomme X., Monier E., Guillou L., Riou B. Short- and long-term prognostic value of postoperative cardiac troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology (2003) 99 270-274.
79. Garcia C., Julier K., Bestmann L. et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br. J. Anaesth. (2005) 94 159-165.
80. Julier K., da Silva R., Garcia C. et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology (2003) 98 1315-1327.
81. Bein B., Renner J., Caliebe D. et al. The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardio-pulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anaesthesia (2008) 63 1046-1055.
82. De Hert S.G., Van der Linden P.J., Cromheecke S. et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology (2004) 101 299-310.
83. Wang X., Jarvinen O., Kuukasjarvi P. et al. Isoflurane produces only minor preconditioning in coronary artery bypass grafting. Scand. Cardiovasc. J. (2004) 38 287-292.
84. Piriou V., Mantz J., Goldfarb G. et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br. J. Anaesth. (2007) 99 624-631.
85. Frassdorf J., Borowski A., Ebel D. et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. (2009) 137, 1436-1442, 42 e1-2.
86. Jia B., Crowder C.M. Volatile anesthetic preconditioning present in the invertebrate Caenorhabditis elegans. Anesthesiology (2008) 108 426-433.
87. Reimer K.A., Murry C.E., Yamasawa I., Hill M.L., Jennings R.B. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am. J. Physiol. (1986) 2 H1306-H1315.
88. Stowe D.F., Camara A.K. Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function. Antioxid. Redox Signal. (2009) 11 1373-1414.
89. Bolli R., Becker L., Gross G. et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ. Res. (2004) 95 125-134.
90. Hausenloy D.J., Baxter G., Bell R. et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res. Cardiol. (2010) 105 677-686.
91. Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. (2007) 59 418-458.